Via Piretti 16 - 40012 Calderara di Reno (BO) Italy +39 051 0562636
Slide Left Slide Right



Pharma and Cosmetics


Chemical Engineering


Training and Education


Research and Development

Oops... Page Not Found! Sorry the Page Could not be Found here.

Try using the button below to go to main page of the site

Go to Back

About us

Innovamol is a consultancy company established by Dr. Alberto Del Rio and Engr. Glauco Del Rio in 2015 providing services in the area of chemical sciences

Our Services

Consulting Services

- CLP regulation
- REACH regulation
- Chemoinformatics
- Data mining and scientific data entry
- Scientific and patent literature searches
- Pharmaceuticals and cosmetics

Project Proposals

- Regional projects
- National projects
- European Projects

Proof of Concept Studies

- Research projects feasibility
- Industrial proof-of-concept
- New business feasibility
- Ad hoc scientific experiments

Corporate Scientific Support

- Research & development support
- Prototyping and product industrialization
- Scientific management and external evaluation

Intellectual Property

- Technological innovation evaluation
- Freedom-to-operate
- Evaluation of patenting potential and patent drafting
- Evaluation of trademark opportunities

Training and Teaching

- Academic institutions
- Industries
- Professional association
- Charities
- Schools


  • portfolio

    Technical consultancy for the innovative plastic sector

  • portfolio

    Consultancy for scientific literature search

  • portfolio

    Advanced course of intellectual property in the chemical field

  • portfolio

    Advanced teaching course in drug discovery and pharmaceutical industry

  • portfolio

    Technical consultancy for food and feed sector

  • portfolio

    Drug design and discovery consultancy

  • portfolio

    Drug design and discovery consultancy

  • portfolio

    Supply of bioactive molecules for research and development

  • portfolio

    Technical consultancy for 3D printing materials

  • portfolio

    Technical consultancy for intellectual property in cosmetics

  • portfolio

    Technical consultancy for pharmaceutical products

  • portfolio

    Organization of scientific events


Deregulated nicotinamide adenine dinucleotide (NAD) biosynthesis and signaling underlies many aspects of carcinogenesis. NAD biosynthetic enzymes, such as nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), are commonly upregulated in cancer cells, where they fuel increased metabolic demands and downstream enzymes involved in DNA repair and in the promotion of cell growth, cell motility, de- differentiation and immune escape. In addition, NAD-producing enzymes, such as NAMPT, moonlight in the extracellular space, exerting strongly pro-oncogenic, autocrine and paracrine effects. Many of these roles of NAD-producing and NAD- utilizing enzymes appear to be shared between solid and haematological cancers.

Thus, agents targeting NAD production or signaling are expected to have broad applicability. INTEGRATA will:
1. develop new NAD biosynthesis and NAD/nucleotide signaling inhibitors;
2. assess pharmacology and toxicity of the new therapeutics in preclinical models;
3. achieve the proof- of-concept of activity of the newly generated agents in relevant in vivo cancer models.

INTEGRATA will train 14 PhD students in an overarching, interdisciplinary training programme that will include training-by-research, joint courses of technical, scientific, and transferrable skills, active participation to public scientific events, and an intense intersectoral networking exchange plan. The INTEGRATA Consortium encompasses academic institutions, research centres, and SMEs/ biotech pharma, all with proven experience in higher education and training, and geared with state-of-the-art scientific and technical expertise and infrastructures.

Technological Partners:

Europe This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 813284

Identification of new SMYD3 inhibitors as potential drugs for the treatment of colorectal carcinoma - As part of the project "Precision Oncology and New Anti-tumor Therapies - ONCOPENTA

Technological Partners:

The POR FESR project has a strong innovative nature in the field of transdermal products (transdermal drug delivery). This route of administration allows bioactive molecules to be gradually absorbed and released into the systemic circulation.
Thanks to the project, InnovaMol has developed a line of products suitable for the following applications and treatments:
- cicatrizing: burns, post-radiotherapy lesions, abrasions;
- collagen restoring: serious dermatological conditions;
- anti-inflammatory: dermatitis and cracking;
- transdermal active ingredients: various applications.
The products come in the form of creams, gels, ointments or lotions.

Technological Partners:


Contact Information

Via Piretti 16 - 40012 Calderara di Reno (BO) Italy

+39 051 0562636



Get In Touch